Arcutis Biotherapeutics, Inc. (ARQT)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 81,504 | 65,846 | 44,755 | 30,858 |
| Selling, general and administrative | 69,170 | - | 58,817 | 58,173 |
| Research and development | 19,453 | - | 19,501 | 19,298 |
| Cost of sales | 7,492 | - | 5,503 | 3,464 |
| Total operating expenses | 96,115 | 90,375 | 83,821 | 80,935 |
| Loss from operations | -14,611 | -24,529 | -39,066 | -50,077 |
| Interest expense | 3,029 | 2,982 | 6,653 | 7,484 |
| Other income, net | 2,096 | 2,730 | 4,182 | 5,229 |
| Loss before income taxes | -15,544 | -24,781 | -41,537 | -52,332 |
| Provision for income taxes | 342 | 279 | - | - |
| Net loss | -15,886 | -25,060 | -41,537 | -52,332 |
| Unrealized loss on marketable securities | -95 | -137 | 771 | -127 |
| Foreign currency translation adjustment | 200 | 4 | 56 | -34 |
| Total other comprehensive income (loss) | 105 | -133 | 827 | -161 |
| Comprehensive loss | -15,781 | -25,193 | -40,710 | -52,493 |
| Net loss per share, basic (in usd per share) | -0.13 | -0.2 | -0.33 | -0.42 |
| Net loss per share, diluted (in usd per share) | -0.13 | -0.2 | -0.33 | -0.42 |
| Weighted-average shares used in computing net loss per share, basic (in shares) | 126,997,000 | 126,036,862 | 124,302,317 | 123,480,849 |
| Weighted-average shares used in computing net loss per share, diluted (in shares) | 126,997,000 | 126,036,862 | 124,302,317 | 123,480,849 |